ArticleRheumatology and therapy2023

Outcomes Following Adalimumab Bio-originator to Biosimilar Switch-A Comparison Using Real-world Patient- and Physician-Reported Data in European Countries.

Peter C Taylor et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.